Since the VMAT2 is a target for reserpine (Erickson et al., 1996) and because patients treated with this drug frequently developed depression (Freis, 1954), we tested if reserpine treatment could mimic responses of VMAT2-HET mice. Here, SLC18A2 is linked to major depressive disorder.